# Effectiveness and Safety of Adipose-Derived Regenerative Cells for Treatment of Glaucomatous Neurodegeneration

> **NCT02144103** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation** · enrollment: 16 (estimated)

## Conditions studied

- Retinal Degeneration
- Primary Open-Angle Glaucoma

## Interventions

- **OTHER:** Subtenon administration of autologous ADRC
- **PROCEDURE:** Liposuction
- **DEVICE:** ADRC isolation

## Key facts

- **NCT ID:** NCT02144103
- **Lead sponsor:** Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-05
- **Primary completion:** 2018-07
- **Final completion:** 2019-01
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2017-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02144103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02144103, "Effectiveness and Safety of Adipose-Derived Regenerative Cells for Treatment of Glaucomatous Neurodegeneration". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02144103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*